Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis
Bibliographic record
Abstract
Abstract BACKGROUND: Posttransplant cyclophosphamide (PTCy) is increasingly utilized as graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic cell transplantation (allo-HCT), including in the mismatched unrelated donor (MMUD) setting. While bone marrow (BM) has traditionally been favored in this context, peripheral blood stem cells (PBSC) remain a widely used alternative. This study aimed to evaluate post-transplant outcomes associated with PBSC versus BM grafts in MMUD allo-HCT recipients receiving PTCy-based GVHD prophylaxis. METHODS: We conducted a retrospective multicenter analysis of adult MMUD allo-HCT recipients from 2017 to 2021 using the publicly available P5891 dataset from the Center for International Blood and Marrow Transplant Research (CIBMTR), as published by Shaffer et al. Patients received PTCy-based GVHD prophylaxis. Outcomes included overall survival (OS), disease-free survival (DFS), relapse, non-relapse mortality (NRM), acute and chronic GVHD, and GVHD-free, relapse-free survival (GRFS). Median follow-up was estimated using the reverse Kaplan-Meier method. Univariable and multivariable Cox proportional hazards models were used to assess associations between graft source and outcomes, adjusting for variables with p < 0.2 in univariable analyses or known clinical relevance. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported. Statistical significance was defined as p < 0.05. RESULTS: A total of 559 adults underwent MMUD allo-HCT with PTCy-based GVHD prophylaxis; 466 (83.4%) received PBSC grafts and 93 (16.6%) received BM. Median recipient age was 58 years (IQR 46–66), and 55.8% were female. Nearly half had Karnofsky performance status <90 (45.8%) and high comorbidity burden (HCT-CI ≥3 in 56.4%). The primary diagnoses included acute myeloid leukemia (AML, 54.0%), myelodysplastic syndromes (MDS, 24.7%), and acute lymphoblastic leukemia (ALL, 21.3%), with most patients in first complete remission (55.6%) at the time of transplant. Conditioning intensity was myeloablative in 40.6%, reduced-intensity in 42.9%, and non-myeloablative in 16.5%. CMV mismatch was present in 46.3%, and median donor age was 29 years (IQR 24–36). At a median follow-up of 35.5 months, the median GRFS was 17.0 months (95% CI, 10.7–26.5). In univariable analysis, BM grafts were associated with lower NRM compared to PBSC (HR 0.49; p = 0.040); however, this association was not significant in multivariable analysis (HR 0.64; p = 0.241). Graft source had no significant association with GRFS (HR 0.99; p = 0.951), DFS (HR 1.01; p = 0.976), OS (HR 0.98; p = 0.931), relapse (HR 1.16; p = 0.549), or GVHD outcomes, including grade II–IV acute GVHD (HR 1.08; p = 0.705), grade III–IV acute GVHD (HR 0.49; p = 0.178), and moderate/severe chronic GVHD (HR 0.82; p = 0.530). Several clinical factors were significantly associated with outcomes. MDS was linked to inferior GRFS (HR 1.49; p = 0.005), DFS (HR 1.39; p = 0.041), OS (HR 1.40; p = 0.044), and higher NRM (HR 2.27; p = 0.001) compared to AML. Karnofsky score <90 predicted worse GRFS (HR 1.38; p = 0.008) and OS (HR 1.46; p = 0.009), with a trend toward inferior DFS (HR 1.26; p = 0.077). HCT-CI ≥3 was associated with worse GRFS (HR, 1.70; p = 0.009) and a higher risk of relapse (HR, 1.85; p = 0.046). Age ≥70 was associated with significantly worse DFS (HR 2.20; p = 0.036), OS (HR 2.41; p = 0.027), and a markedly higher NRM (HR 5.27; p = 0.020). CMV mismatch (+/− vs. +/+) was linked to inferior DFS (HR 1.53; p = 0.024) and higher relapse risk (HR 1.85; p = 0.017). Compared to AML, ALL was associated with a lower relapse risk (HR, 0.48; p = 0.014), but a significantly higher NRM (HR, 3.19; p < 0.0001). Donor aged 25–29 (vs. 18–24) was associated with a higher risk of moderate/severe chronic GVHD (HR 2.04; p = 0.026). Non-myeloablative conditioning was associated with a reduced incidence of grade II–IV acute GVHD (HR 0.52; p = 0.015), without significantly affecting relapse or survival.CONCLUSIONS: In mismatched unrelated donor allo-HCT with PTCy-based GVHD prophylaxis, graft source was not significantly associated with survival, relapse, NRM, or GVHD outcomes after adjusting for clinical variables. Instead, patient age, comorbidity burden, performance status, disease type, and CMV mismatch were the primary determinants of outcome. These findings support the use of PBSC grafts when BM is not feasible and underscore the need for individualized transplant planning.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".